Scarica l'app Stockscreener
4.79
2.35%
0.11
Dopo l'orario di chiusura:
4.81
0.02
+0.42%
Precedente Chiudi:
$4.68
Aprire:
$4.57
Volume 24 ore:
992.91K
Relative Volume:
0.25
Capitalizzazione di mercato:
$497.60M
Reddito:
-
Utile/perdita netta:
$-165.67M
Rapporto P/E:
-2.1699
EPS:
-2.2075
Flusso di cassa netto:
$-113.29M
1 W Prestazione:
-1.24%
1M Prestazione:
-8.41%
6M Prestazione:
+11.92%
1 anno Prestazione:
+117.73%
Intervallo 1D:
$4.51
$4.80
Intervallo di 1 settimana:
$4.21
$4.84
Portata 52W:
$1.61
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Nome
Larimar Therapeutics Inc
Settore
Industria
Telefono
844-511-9056
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.79 | 497.60M | 0 | -165.67M | -113.29M | -2.2075 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Iniziato | Truist | Buy |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-10-03 | Iniziato | Wedbush | Outperform |
| 2024-10-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-03 | Iniziato | Leerink Partners | Outperform |
| 2023-11-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-19 | Iniziato | Guggenheim | Buy |
| 2022-02-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-02-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
LRMR PE Ratio & Valuation, Is LRMR Overvalued - Intellectia AI
Biotech Larimar heads to Miami for back-to-back investor meetings in March - Stock Titan
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital - MarketBeat
LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LRMR Technical Analysis & Stock Price Forecast - Intellectia AI
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Larimar reports results, advances Nomlabofusp toward FDA filing - MSN
Earnings Recap: Does Larimar Therapeutics Inc have consistent dividend growthMarket Growth Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Buyback Watch: Is Larimar Therapeutics Incs growth already priced in2026 Weekly Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Larimar Therapeutics Inc impacted by rising ratesProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - MSN
Profit Recap: Will Larimar Therapeutics Inc stock hit new highs in YEAR2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Insider Monkey
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing - MyChesCo
Larimar Therapeutics (NASDAQ:LRMR) Stock Rating Upgraded by Truist Financial - MarketBeat
RSI Check: Will Larimar Therapeutics Inc benefit from geopolitical trendsWeekly Trading Summary & Consistent Growth Stock Picks - baoquankhu1.vn
Larimar heads to JPMorgan as rare disease program draws investor attention - MSN
Larimar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Larimar surges on FDA breakthrough status for lead asset - MSN
Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday - MarketBeat
Institution Moves: Is Larimar Therapeutics Inc impacted by rising ratesTrade Exit Report & Low Risk Entry Point Tips - baoquankhu1.vn
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade - MarketBeat
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00 - MarketBeat
LRMR Stock: Wedbush Raises Price Target to $13, Maintains Outper - GuruFocus
Larimar Therapeutics (LRMR) Q4 EPS Misses Estimates - GuruFocus
Larimar Therapeutics stock rating reiterated by William Blair - Investing.com Canada
Nomlabofusp push at Larimar Therapeutics (NASDAQ: LRMR) targets 2026 BLA - Stock Titan
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Larimar Therapeutics reports Q4 EPS (73c), consensus (55c) - TipRanks
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar (LRMR) Poised for Milestone Achievements and Financial S - gurufocus.com
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product. - Bitget
Larimar: Q4 Earnings Snapshot - KTVB
Larimar Therapeutics Receives Breakthrough Therapy Designation for Nomlabofusp in Friedreich's Ataxia, Plans BLA Submission for June 2026 - Quiver Quantitative
LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment - TradingView
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Larimar Therapeutics Q4 net loss widens on higher R&D costs - TradingView
Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027 - Stock Titan
BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million - TradingView
FDA grants Breakthrough status to rare disease drug as June filing nears - Stock Titan
IPO Launch: Does Larimar Therapeutics Inc have consistent dividend growth2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Should I invest in Larimar Therapeutics Inc before earningsSwing Trade & Growth Focused Investment Plans - baoquankhu1.vn
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest - MarketBeat
Aug Gainers: How volatile is Larimar Therapeutics Inc stockTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):